CANCER BUZZ
Of the barriers to innovation and adopting new strategies, human hesitation is one of the greatest. Health care is a rapidly evolving field by nature, which is compounded by near constant technological advancement. For insight into overcoming hesitation while navigating frequent change in a burnout-oriented industry, CANCER BUZZ spoke with Michelle Rozen, PhD, behavioral scientist, bestselling author, and keynote speaker at the upcoming 2026 ACCC Leadership Summit. Dr. Rozen shares concrete strategies that oncology leaders can implement in their programs to not just survive, but thrive in an...
info_outlineCANCER BUZZ
In the second installment of Oncology Unscripted, an unfiltered, honest dialogue about the state of cancer care today, hosts Mark Liu and Deirdre Saulet invite Meagan O’Neill, MS, Executive Director of ACCC, to discuss the Association’s plans for the upcoming year, honing in on challenges and opportunities within its membership. O’Neill shares the vision behind expanding the CANCER BUZZ podcast, the continued development of ACCC’s 2030 vision, and how she views crisis as a path forward for innovation. “When I look at 2026, [I look] at crisis as an opportunity...How can we use this...
info_outlineCANCER BUZZ
Advanced practice providers (APPs) are both an integral part of the care team and a driving force behind innovation in oncology. This special state society episode of CANCER BUZZ will explore how oncology APPs are stepping into leadership roles—formally and informally—to advocate for role clarity and equitable compensation, improve mentorship, and elevate the value of APPs within the multidisciplinary cancer care team. Jessica Leibelt, AGNP-C, AOCNP, from Fred Hutchinson Cancer Center, Carlin Callaway, DMP, RN, ACNP-BC, ACNS-BC, AOCNP, from the University of Colorado Cancer Center, and...
info_outlineCANCER BUZZ
Cancer cases, cancer-related deaths, and survivorship are projected to rise exponentially—yet oncology faces critical workforce shortages. In this episode, CANCER BUZZ speaks with Tristan Blanco, a biology major and fellow in VCU Massey’s Cancer-focused Undergraduate Research Experience (CURE) Program, who shares his experience as part of a program designed to scale oncology education and meet the evolving needs of cancer care nationwide. Get behind the scenes of an innovative training model that’s preparing the next generation of oncology leaders. "It’s one of the smartest ways...
info_outlineCANCER BUZZ
Introducing a brand new podcast from ACCC: Oncology Unscripted. In this inaugural episode, hosts Mark Liu and Deirdre Saulet lay out what listeners can expect from the show, including unfiltered, honest dialogue about the state of cancer care today, the most pressing challenges providers are facing, and how they can move forward with hope amid unpredictable headwinds. Liu and Saulet will approach a variety of topics, from operational to financial to clinical, as they explore how providers can help one another, continue to hold important conversations, and act as agents of change in oncology....
info_outlineCANCER BUZZ
CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center’s community-based, outpatient model, impact on outcomes for...
info_outlineCANCER BUZZ
Claudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin 18.2 is shaping treatment decisions and some of the clinical trials pursuing more information about the potential for this biomarker. CANCER BUZZ also speaks with Sasha Watson, PharmD, outpatient...
info_outlineCANCER BUZZ
Relapsed/refractory follicular lymphoma (R/R FL) is challenging to treat, requiring thoughtful clinical decision-making during treatment selection and sequencing. In this episode, CANCER BUZZ speaks with Benjamin Heyman, MD, hematologist and clinical associate professor at City of Hope, about the importance of individualized care, shared decision-making, clinical trial referrals, and multidisciplinary collaboration. CANCER BUZZ also speaks with Laurie Adami, patient advocate with R/R FL, about her real-world experience with multiple lines of therapy, clinical trials, and patient advocacy. ...
info_outlineCANCER BUZZ
After 6 years of bringing listeners key insights into the most pressing topics in oncology, ACCC’s podcast, CANCER BUZZ, has gotten a facelift! In this episode, CANCER BUZZ brings back our first podcast guest, Tina Curtis, DNP, MBA, RN, NEA-BC, executive director of cancer services at Froedtert Hospital. In the June 26, 2019, inaugural CANCER BUZZ episode, Dr. Curtis spoke about her institution’s 24-hour, oncology-only urgent care clinic, which earned the cancer program a 2018 ACCC Innovator Award. Today, she’s returned with her colleague Jayme Cotter to share an update on that program,...
info_outlineCANCER BUZZ
US Veterans are at a heightened risk for lung cancer due to service-related exposures. Integrating clinical research into routine oncology care at the US Department of Veterans Affairs (VA) can help bring clinical trials closer to where Veterans live and improve access to cutting edge therapies. In this episode, CANCER BUZZ speaks with Millie Das, MD, chief of oncology at the VA Palo Alto Health Care System, about the collaborations and institutional support that allowed them to launch lung cancer clinical trials and the role industry has played. “My primary motivation...
info_outlineClinical research is critical to the development of life saving treatments. And ACCC has long supported equitable access to clinical trials, including efforts to ensure that these trials reflect the diversity of the populations they serve. ACCC has made the Just ASK™ Training Program and Site Self-Assessment available free-of-charge to help research sites address barriers to participation in cancer clinical trials among racial and ethnic populations. In this episode, CANCER BUZZ facilities a candid conversation with Glyniss Redman, who received treatment at Gibbs Cancer Center and Research Institute for multiple myeloma, and 2 members of her cancer treatment team: clinical research coordinator Audrianna Carrington and oncologist hematologist Dr. Tondre Buck, about overcoming barriers, ensuring shared decision-making, and improving the inclusion of historically underrepresented groups in clinical trials.
“If you look at cancers in general, treatments have gotten better over the years in almost every category, and we wouldn’t be here if it wasn’t for clinical trials.” – Tondre Buck, MD
“We’re playing the long game here. Some of the information or this research may not be about me. This is about our future generation…so this is a legacy game for me…This is what I’m doing with my [one] wild and precious life. I want to be here as long as I possibly can, but I also want my offspring: my children, my grandchildren, and my great grandchildren to be here as well and [to] have a better experience as far as health care and cancer.” – Glyniss Redman
“We do have to talk about past unethical experimentation and research in order for us to better prepare how we're going to go forward…[transportation] is one barrier that we are tackling. You know, we don't want to put that stress on the patients who have to choose between gas, their physician visit, their food, or their medicine for the day. So that is a huge barrier, and you really want that population to be represented on the trial, because rural populations tend to have higher cancer rates.” – Audrianna Carrington
Tondre Buck, MD
Oncologist Hematologist
Gibbs Cancer Center and Research Institute
Spartanburg, SC
Audrianna Carrington
Clinical Research Coordinator
Gibbs Cancer Center and Research Institute
Spartanburg, SC
Glyniss Redman
Poet and Patient with Multiple Myeloma
Reference:
Unger JM, Shulman LN, Facktor MA, et al. National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data. J Clin Oncol. 2024;42(18):2139-2148. doi:10.1200/JCO.23.01030
Resources:
The Just ASK™ Training Program, Site Self-Assessment, and Training Facilitation Guide
Clinical Research Terms Glossary
Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator
Gibbs Cancer Center and Research Institute